Exploring how Erythropoietin affects blood cell development in humans
Investigating the Cell Type- and Receptor-Specific Effects of Erythropoietin that Mediate Erythropoiesis and Thrombopoiesis in Primary Human Hematopoietic Progenitor Cells
This study is looking at how a hormone called Erythropoietin (EPO) affects the growth of different blood cells in people, especially to help improve treatments for those with anemia, like patients with chronic kidney disease.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project ID | NIH-11085827 on NIH RePORTER |
What this research studies
This research investigates the effects of Erythropoietin (EPO), a hormone that stimulates red blood cell production, on different types of blood progenitor cells in humans. It aims to understand how EPO influences not only the formation of red blood cells but also other blood components, such as platelets, which are crucial for blood clotting. By examining the specific receptors and signaling pathways activated by EPO in these cells, the research seeks to clarify the hormone's broader role in blood cell development. This could lead to improved treatments for patients suffering from anemia, particularly those with chronic kidney disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from anemia due to chronic kidney disease.
Not a fit: Patients who do not have chronic kidney disease or anemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for anemia in patients with chronic kidney disease.
How similar studies have performed: Previous research has shown promising results in understanding the role of EPO in blood cell development, but this specific investigation into its effects on different progenitor cells is relatively novel.
Where this research is happening
Farmington, United States
- University of Connecticut Sch of Med/dnt — Farmington, United States (Active)
Researchers
- Principal investigator: Scanlon, Vanessa M. — University of Connecticut Sch of Med/dnt
- Study coordinator: Scanlon, Vanessa M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.